Avalyn Pharma is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including Idiopathic Pulmonary Fibrosis (IPF) and other Interstitial Lung Diseases (ILD).

Avalyn Pharma

Avalyn is a clinical-stage biopharmaceutical company developing inhaled therapies to treat rare respiratory diseases, including idiopathic pulmonary fibrosis and other interstitial lung diseases. Our lead candidate, AP01, is a Phase 2b-ready inhaled formulation of pirfenidone in development for the treatment of pulmonary fibrosis

Avalyn Pharma Inc.

Celebrating the remarkable achievements of Lyn Baranowski and all #WomenInScience! Your groundbreaking work continues to inspire us all.

Avalyn announced this morning that Lyn Baranowski, Chief Executive Officer, will participate in three upcoming investor conferences.

For more details: https://lnkd.in/g2pe-Nij

Avalyn is excited to welcome Scott Beardsley of Novo Ventures (US) to our Board of Directors. With Scott’s extensive background as an investor and expert in financing, we know his guidance will be instrumental in helping take Avalyn to its next stages of growth. We bid farewell to Peter Moldt, who is stepping off our Board, and we want to recognize and thank him for his contributions to the company. We are deeply grateful to Peter and the entire team at Novo Ventures for their partnership and helping drive our lead inhaled #pulmonaryfibrosis treatment candidates forward into the clinic.

Avalyn CEO Lyn Baranowski is participating in a virtual panel discussion later today hosted by Boost by BioBreak. Join us for a lively discussion on biotech fundraising led by Stephanie Oestreich, Managing Director of Myeloma Investment Fund, and featuring fellow biotech leaders Lital Gilad-Shaoulian of PurposeBio and Catherine Sabatos-Peyton of Larkspur Biosciences.

Register here: https://lnkd.in/gm3afDZU

#leadership #womenleaders #femaleleadership #biotech #lifesciences #BoostbyBioBreak

In the early days of Lyn Baranowski’s career, she was struck by how little research and development was going on with lung diseases and how critical these illnesses are. Today, she is the CEO of Avalyn Pharma Inc. and brings more than two decades of experience leading a vast array of functions in biotech, big pharma, and venture capital firms with a focus on the respiratory therapeutic area.

Baranowski has a passion for working in smaller companies, building teams and pipelines, and making a difference which is clear to her peers. At the end of September, Avalyn closed an oversubscribed $175 million Series C financing to now support a lot of exciting initiatives in the works.

Learn more in our latest #BehindTheBreakthrough spotlight – link in comments. 

#biotech #healthcare #startupstories
Ketan Patel

Avalyn announced this morning that Lyn Baranowski, Chief Executive Officer, will provide a corporate overview presentation and participate in a fireside chat at the upcoming 2023 RBC Capital Markets Healthcare Private Company Conference. Management will also participate in one-on-one meetings with investors at the conference. For more details: https://lnkd.in/gVXpnV6w

Avalyn is committed to advancing the treatment of #pulmonaryfibrosis (PF) for patients across the globe, and supporting the professional development of the #researchers working to develop innovative treatments for PF is integral to this goal.

We are proud to sponsor the Centre of Research Excellence in Pulmonary Fibrosis and the CREATE Professional Development Weekend, which aims to equip the next generation of researchers with the training and skills to lead PF research.

We are excited to engage with the #PF community at the Pulmonary Fibrosis Foundation PFF Summit 2023, where we will present data from our AP01 and AP02 inhaled therapeutics programs. Three posters will be presented today from 5:00 – 8:00 p.m. ET, and you can find us at booth #204 throughout the Summit.

For more details: https://lnkd.in/gmqrmg3m

We couldn’t be happier to announce the newest members of the Avalyn team! Join us in welcoming the following accomplished individuals to Avalyn.
 
Craig Conoscenti,MD,FCCP,ATSF: Senior Vice President, Clinical Development
Jim Bishop: Senior Vice President, Business Operations
Allison Trucillo, MD: Vice President, Medical Affairs
Rebecca Boone: Vice President, Clinical Operations

Read our press release here: https://lnkd.in/efnVpAVt

We’re incredibly proud of the dedication to the #pulmonaryfibrosis patient community that our employees demonstrate both inside Avalyn and in their personal lives.
 
Today, we’re highlighting Samiran De, who participated in the Pulmonary Fibrosis Foundation (PFF) National Walk Day in memory of his uncle, a #PF patient who passed away after a year-and-a-half battle with the disease. The Samiran De Team achieved its fundraising goal to help support the PF community.

msh id	COM:AVALYNPHARMA
symbol	-
name	Avalyn Pharma
homepage url	https://avalynpharma.com
country	US
sector	8
industry	Healthcare & Health Services
market	PRIVATE
employee count	29
crunchbase url	https://www.crunchbase.com/organization/avalyn-pharma/signals_and_news
linkedin url	https://www.linkedin.com/company/avalyn-pharma-inc
founders	-

market cap	-
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	-
monthly webtraffic growth	-
growth score 14	9.49
growth score 28	15.51
growth score 90	13.21
growth score 365	12.15

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	-
growth cost of revenue	-
growth depreciation and amortization	-
growth ebitda	-
growth ebitda ratio	-
growth eps	-
growth eps diluted	-
growth general and administrative expenses	-
growth gross profit	-
growth gross profit ratio	-

COM:AVALYNPHARMA

Avalyn Pharma

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	-
cost of revenue	-
depreciation and amortization	-
ebitda	-
ebitda ratio	-
eps	-
eps diluted	-
operating expenses	-
operating income	-
operating income ratio	-

accounts receivables	-
capital expenditure	-
cash at beginning of period	-
cash at end of period	-
inventory	-
working capital ttm	-

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-